Phenotypic and Genetic Characterization and Production Abilities of <i>Lacticaseibacillus rhamnosus</i> Strain 484—A New Probiotic Strain Isolated From Human Breast Milk

Recent studies suggest that human breast milk (HBM) is a promising source of probiotic bacteria with potential applications in both medicine and the food industry. Probiotic bacteria, particularly species of the genus <i>Lactobacillus</i>, are classified as lactic acid bacteria (LAB). However, probiotic properties are strain-specific, as not all <i>Lactobacillus</i> strains exhibit health benefits or inhibit pathogens. This study evaluated the probiotic potential of a newly isolated strain, <i>Lacticaseibacillus rhamnosus</i> strain 484, derived from human milk. Phenotypic and genomic analyses were performed, with <i>L. rhamnosus</i> 1.0320 serving as a reference genome. We focused on strain safety for human use and potential health benefits. Strain 484 underwent probiotic characterization and demonstrated strong auto- and co-aggregation abilities, contributing to effective pathogenic bacteria inhibition. The strain also showed bile tolerance, antibiotic sensitivity, and lacked hemolytic and catalase activity, indicating safety and suitability profiles for oral administration. Its resistance to low pH and bile salts indicated survival during gastrointestinal transit and intestinal colonization. Notably, cell surface hydrophobicity (CSH) exceeded that of the well-known <i>L. rhamnosus</i> GG strain, potentially enhancing adhesion to intestinal epithelial cells. Genomic analysis confirmed no antibiotic resistance genes (ARGs) and plasmids, suggesting genetic stability. Overall, <i>L. rhamnosus</i> 484 appears to be a safe and promising probiotic candidate with potential applications in both medical and food-related fields, particularly for oral use in preventing and controlling common pathogens.